Berlin-Chemie Menarini in the news

Berlin-Chemie, a pharmaceutical company part of the Menarini Group, has over 130 years of experience in pharmaceutical product development, production, and distribution across over 90 global markets.

Menarini acquires licensing rights from Gan & Lee to commercialize Bofanglutide, a bi-weekly GLP-1 agonist for weight management, across 39 European countries.

Markus Schöne moves from Berlin-Chemie Menarini to lead healthcare research at YouGovPsychonomics.

Berlin-Chemie AG is ranked as the 580th most important company in Germany within the pharmaceutical industry sector.

Berlin-Chemie, a German pharmaceutical company with around 5,000 employees, is part of the Italian Menarini Group, managing its pharmaceutical business in Germany, Eastern Europe, and the CIS region.

Menarini, an Italian pharmaceutical company, specializes in oncology and cardiology, generating 4.9 billion euros in revenue in 2025 with a strong international presence, including a significant footprint in Germany and the US.

Berlin-Chemie partners with 1. FC Union Berlin, supporting both teams and leveraging shared East Berlin heritage for marketing and employer branding.

Berlin-Chemie Menarini integrates employees with disabilities into its core pharmaceutical production with fair pay and high economic output.

Berlin-Chemie renews its partnership with 1. FC Union Berlin to support both Bundesliga teams and youth education initiatives in Berlin.

Han Steutel has joined the board of Berlin-Chemie AG, marking a key personnel update.

Berlin-Chemie integrates about 30 disabled employees in a supportive protected department, contributing significantly to production with fair wages and inclusive practices.

Berlin-Chemie is recognized for its inclusive employment of people with disabilities in the pharmaceutical industry.

Western companies' exit from Russia after the Ukraine invasion has caused shortages of essential medicines, as explained by Berlin-Chemie.

Russia is experiencing a shortage of a vital medicine as Western companies, including Berlin-Chemie, have withdrawn from the country following the invasion of Ukraine.

Berlin Chemie sponsors 1. FC Union Berlin to boost regional brand awareness, promote careers, and collaborate on social projects.

Berlin-Chemie AG, part of the Menarini Group, reported a positive balance in 2003 with a 25% increase in turnover to 503 million Euros and an increase of 650 employees, despite facing new compulsory discounts on innovative medicines.

A. Menarini Diagnostics partnered with Sinocare to exclusively distribute the GlucoMen® iCan rtCGM system across Europe, launching in Germany in late 2025 with a highly accurate, 15-day wearable glucose sensor.

A. Menarini Diagnostics will exclusively distribute Sinocare's GlucoMen® iCan rtCGM system across Europe, launching in Germany in late 2025 to enhance diabetes management.

Berlin-Chemie operates a protected department employing people with disabilities to produce medication labels, emphasizing flexibility and valuing their contributions.

Berlin-Chemie in Adlershof integrates workers with disabilities into its production line, maintaining inclusion since DDR times.